Browsing by Author Links, Matthew

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 8 of 8
Issue DateTitleAuthor(s)Citation
2017Checkpoint Inhibitors in Metastatic EGFR-Mutated Non`Small Cell Lung Cancer A Meta-AnalysisGebski, Val; Lee, Chee Khoon; Lord, Sarah (Sally); Links, Matthew; Man, J; Mok, Tony; Yang, J; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreCheckpoint Inhibitors in Metastatic EGFR-Mutated Non`Small Cell Lung Cancer A Meta-Analysis, Journal of Thoracic Oncology, vol.12, 2, 2017,pp 403-407
2015Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-AnalysisDing, Pei Ni; Gebski, Val; Lee, Chee Khoon; Lord, Sarah (Sally); Pavlakis, Nick; Gralla, Richard J; Inoue, Akira; Links, Matthew; Mitsudomi, Tetsuya; Rosell, Rafael Costa; Wu, Yi-long; Yang, James Chic-Hsin; Zhou, Ci-Xiang; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: MedicineImpact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis, Journal of Clinical Oncology, vol.33, 17, 2015,pp 1958-1965
2005Phase II study of docetaxel and celecoxib as first or second line therapy in patients with advanced NSCLCBoyer, Michael; Hui, Rina; Yip, Desmond; Blackwell, T.; Chern, B.; Crombie, C.; Hawson, G.; Links, Matthew; Underhill, Craig; Central Clinical School: Medicine; Western Clinical School: Medicine (Westmead); MedicinePhase II study of docetaxel and celecoxib as first or second line therapy in patients with advanced NSCLC, Lung cancer, vol.49,(Sup.2),2005,pp S272-S273
2007Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group studyBeale, Philip; Harnett, Paul; Allan, S; Buck, M; Davies, T; De Souza, P; Fitzharris, B; Goldrick, A; Kalimi, G; Links, Matthew; Stuart-Harris, R; Central Clinical School: Medicine; Western Clinical School: Medicine (Westmead)Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study, International Journal Of Gynecological Cancer, vol.17,(2),2007,pp 359-366
2008Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rateJiang, Xuemin; McLachlan, Andrew; Galettis, Peter; Links, Matthew; Mitchell, Paul L.; Pharmacy; PharmacyPopulation pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate, British Journal of Clinical Pharmacology, vol.65, 3, 2008,pp 326-333
2009Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 TrialSimes, Robert John; Tebbutt, Niall; Zalcberg, John; Au, Heather-Jane; Australasian Gastrointestinal Interest, Group; Colwell, Bruce; Evans, William K.; Findlay, Brian; Gibbs, Peter; Isogai, Pierre K.; Jonker, Derek J.; Karapetis, Christos; Links, Matthew; Mittman, Nicole; Moore, Malcolm; O'Callaghan, Chris; Siddiqui, Jehan; Tu, D.; Working Group on Economic Analysis of the National Cancer Institute of Canada, Clinical Trials Group; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreProspective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial, Journal of the National Cancer Institute, vol.101, 17, 2009,pp 1182-1192
2017Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare targetClarke, Stephen; Cooper, Wendy Anne; Gill, Anthony; Horvath, Lisa; Li, Bob; O'Toole, Sandra; Pavlakis, Nick; Yu, Bing; Kohonen-Corish, Maija R.J.; Lee, Adrian; Links, Matthew; Lum, Trina; Selinger, Christina; Tran, Thang N.; Yip, Po; Northern Clinical School: Kolling Institute; Central Clinical School: Medicine; Northern Clinical School: Pathology; Central Clinical School: Medicine; Central Clinical School: Pathology; Central Clinical School: Pathology; Northern Clinical School: Medicine; Central Clinical School: MedicineScreening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target, Histopathology, vol.70, 3, 2017,pp 402-411
2005What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?Boyle, Frances; Duric, Vlatka; Stockler, Martin; Stuart-Harris, Robin; Wilcken, Nicholas; Beith, Jane M.; Friedlander, Michael; Links, Matthew; McLachlan, Sue Anne; Meiser, Bettina; Phillips, Kelly-Anne; Taylor, Alan; Thewes, Belinda; Central Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Medicine; Western Clinical School: Medicine (Westmead)What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?, Lancet Oncology, vol.6,(8),2005,pp 581-588